Misplaced Pages

Anagliptin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Anagliptin
Clinical data
Trade namesSuiny
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Approved in Japan
Identifiers
IUPAC name
  • N--2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolopyrimidine-6-carboxamide
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H25N7O2
Molar mass383.456 g·mol
3D model (JSmol)
SMILES
  • CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC3C#N
InChI
  • InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
  • Key:LDXYBEHACFJIEL-HNNXBMFYSA-N

Anagliptin (INN; trade name Suiny) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It is approved for use in Japan. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".

References

  1. Graul AI, Lupone B, Cruces E, Stringer M (January 2013). "2012 in review - part I: the year's new drugs & biologics" (PDF). Drugs of Today. 49 (1): 33–68. doi:10.1358/dot.2013.49.1.1933991. PMID 23362494. Archived from the original (PDF) on 2013-11-03.
  2. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. (December 2011). "Discovery and pharmacological characterization of N--2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolopyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor". Bioorganic & Medicinal Chemistry. 19 (23): 7221–7. doi:10.1016/j.bmc.2011.09.043. PMID 22019046.
Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)
Insulins / insulin analogs
fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
  • Exubera
  • Afrezza
Non-insulins
Insulin sensitizers
Biguanides
TZDs/"glitazones" (PPAR)
Dual PPAR agonists
Amylin analogs and DACRAs
Secretagogues
KATP
Sulfonylureas
Meglitinides/"glinides"
GLP-1 receptor agonists
GLP1 poly-agonist peptides
DPP-4 inhibitors/"gliptins"
Other
Aldose reductase inhibitors
Alpha-glucosidase inhibitors
SGLT2 inhibitors/"gliflozins"
Other
Combinations
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: